Back to top
more

ARAVIVE (ARAV)

(Delayed Data from NSDQ)

$0.04 USD

0.04
NA

0.00 (0.00%)

Updated Jan 26, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of 60% and 27.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 3.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Aravive (ARAV) have performed compared to their sector so far this year.

Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of 33.33% and 98.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 24.11% and 0.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

What Makes Aravive (ARAV) a New Buy Stock

by Zacks Equity Research

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aravive (ARAV) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Tirthankar Chakraborty headshot

Beat the Market the Zacks Way: Boeing, General Electric, AmerisourceBergen, Kimberly-Clark in Focus

by Tirthankar Chakraborty

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of 20.31% and 298.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -12.28% and 4.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Roivant Sciences Ltd. (ROIV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of 1.61% and 20.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -53.33% and 264.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Aravive (ARAV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aravive (ARAV) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aravive (ARAV) delivered earnings and revenue surprises of 3.12% and 36.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -22.64% and 9.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is Aravive (ARAV) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aravive (ARAV) and Cerner (CERN) have performed compared to their sector so far this year.

G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 8.74% and 6.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?